HCG (human chorionic gonadotropin) research and evidence overview

HCG is one of the few compounds in this reference where the evidence question has a clean answer, because the answer differs by indication. For ovulation induction, assisted reproduction, and hypogonadotropic hypogonadism, HCG is an FDA-approved prescription drug with decades of controlled data behind it. For weight loss, it has been tested repeatedly and failed, and its own approved labeling says so in capital letters.

That split makes HCG a useful case study in how evidence quality varies within a single molecule. Strength in one indication carries no information about another.

HCG signals through the LH/HCG receptor, activating the intracellular pathways that drive gonadal steroidogenesis (StatPearls, Human Chorionic Gonadotropin). Because it mimics luteinizing hormone, an exogenous bolus can substitute for the natural LH surge—the basis of its use as an ovulation trigger before oocyte retrieval or insemination.

The FDA-approved labeling for chorionic gonadotropin (Pregnyl, DailyMed) lists three indications: prepubertal cryptorchidism not caused by anatomical obstruction; selected cases of hypogonadotropic hypogonadism in males; and induction of ovulation and pregnancy in anovulatory infertile women whose anovulation is not due to primary ovarian failure and who have received appropriate gonadotropin pretreatment.

The same StatPearls review notes the diagnostic side of HCG measurement, where assay behavior matters: false positives occur in roughly 1 in 1,000 to 1 in 10,000 tests, the "hook effect" can produce false negatives above roughly 500,000 mIU/mL, and commercial assays have shown up to 50-fold variation between platforms.

In men with pathological gonadotropin deficiency, HCG stimulates Leydig-cell testosterone production and can restart sperm production that pituitary failure has silenced. A 2025 systematic review and meta-analysis in Clinical Endocrinology (PMID 39445789) pooled 41 studies covering 1,673 patients with a mean age of 25 and quantified what gonadotropin therapy actually achieves:

• Mean sperm concentration after a median 18 months of treatment was 11.6 million/mL (95% CI 8.4–14.9).
• Sperm was detectable at all in 78% of patients; 55% exceeded 1 M/mL, 36% exceeded 5 M/mL, 24% exceeded 10 M/mL, and 15% exceeded 20 M/mL.
• Combined hCG plus FSH outperformed hCG alone on every sperm threshold measured.
• Men with congenital hypogonadotropic hypogonadism responded less well than those with acquired hypopituitarism.

The authors' own caveat is the important one: while most men produced some sperm, the concentrations typically needed for natural conception were reached far less often. Treatment works, but "works" here means a measured probability, not a guarantee.

The "HCG diet" traces to Albert Simeons' 1950s protocol pairing HCG injections with a roughly 500-calorie daily intake. It has been formally evaluated. A criteria-based meta-analysis in the British Journal of Clinical Pharmacology (PMID 8527285) traced 8 controlled and 16 uncontrolled trials and scored each for methodological quality on a 100-point scale. Scores ranged from 16 to 73, indicating generally poor design. Of the 12 studies scoring 50 or above—all of them controlled—exactly one reported HCG as a useful adjunct. The authors concluded there is no scientific evidence that HCG produces weight loss, fat redistribution, reduced hunger, or improved well-being.

Regulatory labeling reaches the same conclusion. The Pregnyl label states, in its own capitalization, that "HCG HAS NOT BEEN DEMONSTRATED TO BE EFFECTIVE ADJUNCTIVE THERAPY IN THE TREATMENT OF OBESITY," that there is no substantial evidence it increases weight loss beyond caloric restriction, improves fat distribution, or decreases hunger, and elsewhere that "HCG HAS NO KNOWN EFFECT ON FAT MOBILIZATION, APPETITE OR SENSE OF HUNGER, OR BODY FAT DISTRIBUTION." A drug label explicitly disclaiming a popular off-label use is uncommon; here it exists because the use was popular enough to require one.

Weight lost on the protocol is attributable to the severe calorie restriction it prescribes, which is also where its risks sit.

With HCG, the first question about any study is which indication it addresses. Trial evidence in reproductive endocrinology comes from populations with defined hormonal deficits, monitored dosing, and hormone or pregnancy endpoints—none of which transfers to a general wellness context. The second question is whether the comparator was placebo or an uncontrolled before-and- after, since the obesity literature shows exactly how far apart those two designs land.